Cyclosporine for dry eye associated with nivolumab: A case progressing to corneal perforation

Cornea

Volumn 35, Issue 3, 2016, Pages 399-401

  Nguyen, Alexander T ^a   Elia, Maxwell ^a   Materin, Miguel A ^a,b   Sznol, Mario ^b   Chow, Jessica ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

Anti pd 1; Chemotherapy; Cornea; Dry eye; Nivolumab; Perforation

Indexed keywords

ARTIFICIAL TEAR; ASCORBIC ACID; CYCLOSPORIN; DOXYCYCLINE; LOTEPREDNOL; NIVOLUMAB; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BANDAGE CONTACT LENS; BURNING SENSATION; CASE REPORT; CORNEA PERFORATION; DISEASE SEVERITY; DRUG WITHDRAWAL; DRY EYE; FEMALE; FOLLOW UP; HUMAN; KNEE MENISCUS RUPTURE; MALE; METASTATIC MELANOMA; MIDDLE AGED; PATIENT REFERRAL; PRIORITY JOURNAL; TREATMENT DURATION; CHEMICALLY INDUCED; CORNEAL PERFORATION; DRY EYE SYNDROMES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CORNEAL PERFORATION; CYCLOSPORINE; DRY EYE SYNDROMES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84959082340     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000000724     Document Type: Article

References (7)

1. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PDL1 antibody in patients with advanced cancer. N Engl J Med. 2012;366: 2455-2465.
2. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (Checkmate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257-265.
3. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-133.
4. de Valasco G, Bermas B, Choueiri TK. Auto-immune arthropathy and uveitis and complications from PD-1 inhibitor. Arthritis Rheumatol. 2015. doi:10.1002/art.39406. Advance online publication.
5. Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea. 2007;26:805-809.
6. Tough DF, Sprent J. Life span of naïve and memory T cells. Stem Cells. 1995;13:242-249.
7. Chen M, Gong L, Sun X, et al. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, doubleblind, parallel-group trial. J Ocul Pharmacol Ther. 2010;26:361-366.